


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-6 (cancelled)

7. (currently amended) A method of synergistically enhancing the chemotherapeutic treatment of cancer expressing adenosine A₃ receptors comprising administering to a mammal, in need thereof, an effective amount of a high affinity adenosine A₃ receptor antagonist either prior to or during administration of a chemotherapeutic cancer agent characterized by developing P-glycoprotein (P-gp) or multi-drug resistance-associated protein (MRP) dependent multi-drug resistance (MDR), wherein the high affinity adenosine A₃ receptor antagonist has the effect of inhibiting the P-gp or MRP mediated drug-efflux thereby suppressing countering MDR, and wherein the high affinity adenosine A₃ receptor antagonist is a compound of the formula:



wherein:

A is pyrazole;

R² is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;

R³ is furan;

R⁶ is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle;

or a pharmaceutically acceptable salt thereof.

8. (previously presented) The method of claim 7 wherein R² is alkyl.

Claims 9 and 10 (cancelled)

11. (previously presented) The method of claim 7 wherein the cancer is selected from the group consisting of human leukemia, melanoma, pancreatic carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, lung carcinoma, histiocytic lymphoma, astrocytoma and keratinocytoma.

12. (previously presented) The method of claim 7 wherein the cancer has multi-drug resistance that is P-glycoprotein dependent.

13. (previously presented) The method of claim 12 wherein the chemotherapeutic cancer agent is a taxane family compound.

14. (previously presented) The method of claim 12 wherein the chemotherapeutic cancer agent is a vinca alkaloid compound.

15. (previously presented) The method of claim 12 wherein the chemotherapeutic cancer agent is a camptothecin compound.

16. (previously presented) The method of claim 12 wherein the chemotherapeutic cancer agent is an antibiotic compound.

Claims 17 and 18 (cancelled)

19. (previously presented) The method of claim 12 wherein R² is alkyl.

Claims 20-27 (cancelled)

28. (previously presented) The method of claim 19 wherein the chemotherapeutic cancer agent is a taxane family compound.

29. (previously presented) The method of claim 19 wherein the chemotherapeutic cancer agent is a vinca alkaloid compound.

30. (previously presented) The method of claim 19 wherein the chemotherapeutic cancer agent is a camptothecin compound.

31. (previously presented) The method of claim 19 wherein the chemotherapeutic cancer agent is an antibiotic compound.

32. (previously presented) The method of claim 19 wherein the cancer is selected from the group consisting of human leukemia, melanoma, pancreatic carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, lung carcinoma, histiocytic lymphoma, astrocytoma and keratinocytoma.
33. (previously presented) The method of claim 32 wherein the high affinity adenosine A₃ receptor antagonist is selected from the group consisting of MRE3008F20, MRE3046F20, MRE3055F20, MRE3062F20, IL-10 and IL11.
34. (previously presented) The method of claim 33 wherein the taxane family compound is selected from the group consisting of paclitaxel and docetaxel.
35. (previously presented) The method of claim 33 wherein the vinca alkaloid compound is vinblastine.
36. (previously presented) The method of claim 33 wherein the camptothecin compound is irinotecan.
37. (previously presented) The method of claim 33 wherein the antibiotic compound is doxorubicin.
38. (previously presented) The method of claim 19 wherein the high affinity adenosine A₃ receptor antagonist is selected from the group consisting of MRE3008F20, MRE3046F20, MRE3055F20, MRE3062F20, IL-10 and IL11.
39. (previously presented) The method of claim 38 wherein the taxane family compound is selected from the group consisting of paclitaxel and docetaxel.
40. (previously presented) The method of claim 38 wherein the vinca alkaloid compound is vinblastine.
41. (previously presented) The method of claim 38 wherein the camptothecin compound is irinotecan.
42. (previously presented) The method of claim 38 wherein the antibiotic compound is doxorubicin.